頁籤選單縮合
| 題 名 | 晚期前列腺癌之合併雄激素阻斷法=Combined Androgen Blockade for Advanced Prostate Cancer |
|---|---|
| 作 者 | 陳昶名; | 書刊名 | 藥學雜誌 |
| 卷 期 | 31:2=123 2015.06[民104.06] |
| 頁 次 | 頁61-65 |
| 分類號 | 418.275 |
| 關鍵詞 | 晚期前列腺癌; 雄激素剝奪療法; 去勢作用; 促性腺激素釋放荷爾蒙致效劑; 抗雄激素藥物; 合併雄激素阻斷法; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 晚期前列腺癌的第一線治療選擇為荷爾蒙療法。由於前列腺癌的惡化除了受到睪 固酮的影響之外,還會受到腎上腺所分泌之雄激素的影響,因此才有了合併雄激素阻 斷法 (combined androgen blockade) 的出現,然而合併雄激素阻斷法的效果在1990年代 仍未被確立。近年來一些大型統合分析則顯示,相較於單一療法,使用非固醇類的抗 雄激素受體阻斷劑 (non-steroidal androgen receptor antagonist) 的合併療法,在存活率 上有著微小但具統計上差異的成效。然而,在長期使用上,須考量合併雄激素阻斷法 可能帶來更多的副作用。本文章即是回溯過去的研究,探討此療法在晚期前列腺癌上的成效。 |
| 英文摘要 | Hormone therapy is the first-line treatment for advanced prostate cancer. Due to the deterioration of prostate cancer affected by testosterone and androgens secreted by adrenal glands, the treatment called combined androgen blockade (CAB) appeared. In the 1990s, the efficacy of CAB has not been confirmed. In recent years, comparing to the monotherapy of surgical or medical castration, some large meta-analysis found statistically significant but small difference in survival that favored combined androgen blockade with non-steroidal androgen receptor antagonist. On the other hand, CAB may lead to more side effects in the long-term use. This article focused on the efficacy of CAB for advanced prostate cancer. |
本系統中英文摘要資訊取自各篇刊載內容。